Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Japan Approves 1st Oncolytic Virus, Delytact, for Malignant Glioma
June 14, 2021
- Ono to Ditch Foipan Development for COVID-19 as it Misses Goal in Japan PIII
June 14, 2021
- Astellas, Otsuka, Meiji Joining Workplace Vaccination Campaign
June 11, 2021
- NanoCarrier Gene Therapy VB-111 Enters PIII in Japan
June 11, 2021
- Global Pharma Market Grows to US$1.18 Trillion in 2020, with Humira Maintaining No. 1 Title: IQVIA
June 11, 2021
- US Biotech Zogenix Launches Japan Arm, Dravet Syndrome Med Filing Eyed in 2021
June 11, 2021
- Takeda Boasts 10-Plus Immune-Harnessing Compounds in Early Pipeline: Oncology Update
June 10, 2021
- Eisai CEO Says Aducanumab Price Tag Reflects Its Value, 1 Million Patients Estimated in Japan
June 10, 2021
- Kitasato Institute, Meiji Kick Off R&D of Ivermectin Derivatives-Based COVID-19 Meds
June 10, 2021
- Nippon Chemiphar, Sumitomo Dainippon Team Up on Antidepressant R&D
June 10, 2021
- Aducanumab Gets Accelerated OK, Expert Says FDA Verdict Would Affect Japan Review Too
June 9, 2021
- Novo, Chiba University, Asahi City Join Hands to Combat Diabetes
June 9, 2021
- Takeda Chips in for Govt’s Workplace COVID-19 Immunization Drive
June 9, 2021
- Japan Drug Makers Derive Near-60% of FY2020 Sales Overseas as Home Market Falters: Tally
June 8, 2021
- FDA Approves Aducanumab, 1st Disease-Modifying Therapy for Alzheimer’s
June 8, 2021
- Japan Ethical Drug Sales Down 2.4% in April: Crecon
June 8, 2021
- Keytruda Retrieves Top-Selling Crown in Japan in May: Encise
June 8, 2021
- Daiichi Sankyo’s ADC U3-1402 Scores 39% ORR for EGFR-Mutated NSCLC in PI
June 8, 2021
- Bristol Myers, Other Pharma Players Moving to Join Workplace Vaccination Campaign
June 7, 2021
- Kobayashi Kako’s 116-Day Suspension Over, but No Timeline for Resumption
June 7, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…